Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine for Gait and Cognition in PDD
NCT03840837Phase 4Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2019
- Primary completion
- Apr 2020
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivastigmine in Parkinson's disease dementia (PDD) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Timed-Up-and-Go duration at 12 weeks and NeuroTrax Executive Function score at 12 weeks. Started May 2019; status: completed.
02
Drugs
rivastigmine
03
Conditions
Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT03840837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840837.